Videos
Open Access Agreements with Wiley
Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
Articles
Indoor visible moulds and rhinitis in adults: the EGEA study
Orsi, L., Savouré, M., Bousquet, J., et al. Allergy. First published: 22 September 2022
Diagnostic value of a medical algorithm for investigation of perioperative hypersensitivity reactions
Sverrild, A., Carruthers, J., Murthee, K.G., et al. Allergy. First published: 22 September 2022
Nucleoside-modified mRNA vaccines yield robust blocking antibody responses against major house dust mite allergens
Jitthamstaporn, S., Inthong, R., Audomsun, D., et al. Allergy. First published: 22 September 2022
Implementation of the web-based calculator estimating odds ratio of severe COVID-19 for unvaccinated individuals in a country with high coronavirus-related death toll
Kwasniewski, M., Korotko, U., Chwialkowska, K., et al. Allergy. First published: 21 September 2022
Legends of allergy and immunology: Lorenzo Moretta – unfolding the mysteries of NK cells and much more
Canonica, G.W. and Fauci, A.S. Allergy. First published: 20 September 2022
Legends of allergology and immunology: Alex Straumann
Simon, H.-U. Allergy. First published: 20 September 2022
Effect of indoor air pollution on atopic dermatitis in dogs
Lee, J.-H., Kang, B.-T. and Kim, H.-J. Allergy. First published: 20 September 2022
Disproportionate rate of female referrals for suspected COVID-19 vaccine allergies
Chiang, V., Kan, A.K.C., Yim, J.S.H., et al. Allergy. First published: 20 September 2022
Skin biomarkers predict development of atopic dermatitis in infancy
Rinnov, M.R., Halling, A.-S., Gerner, T., et al. Allergy. First published: 16 September 2022
Same dose of Japanese cedar pollen sublingual immunotherapy tablets is optimal for allergic rhinitis caused by either Japanese cedar or Japanese cypress pollen
Gotoh, M., Kurokawa, T., Yonekura, S., et al. Allergy. First published: 15 September 2022
The maternal prenatal and offspring early-life gut microbiome of childhood asthma phenotypes
Lee-Sarwar, K.A., Chen, Y.-C., Chen, Y.Y., et al. Allergy. First published: 15 September 2022
The changes of eosinophil counts in patients after treatment of dupilumab: A systematic review and meta-analysis
Zhou, B., Liang, S., Shang, S., Xiang, L. and Li, L.. Allergy. First published: 15 September 2022
circS100A11 enhances M2a macrophage activation and lung inflammation in children with asthma
Liang, Q., Fu, J., Wang, X., et al. Allergy. First published: 14 September 2022
Allergen recognition by specific effector Th2 cells enables IL-2-dependent activation of regulatory T cell responses in humans
Lozano-Ojalvo, D., Tyler, S.R., Aranda, C.J., et al. Allergy. First published: 12 September 2022
Efficacy of FP-025, a novel Matrix metalloproteinase-12 (MMP-12) inhibitor in murine allergic asthma
Ravanetti, L., Dekker, T., Guo, L., et al. Allergy. First published: 12 September 2022
Real-world evidence for the long-term effect of allergen immunotherapy: current status on database-derived European studies
Vogelberg, C., Klimek, L., Brüggenjürgen, B. and Jutel, M. Allergy. First published: 08 September 2022
Obesity in women with asthma: baseline disadvantage plus greater small-airway responsiveness
Bourdin, A., Bommart, S., Marin, G., et al. Allergy. First published: 07 September 2022
Epithelial cell-expressed type II IL-4 receptor mediates eosinophilic esophagitis
Avlas, S, Shani, G, Rhone, N, et al. Allergy. First published: 07 September 2022
Allergic disease trajectories up to adolescence: Characteristics, early-life and genetic determinants
Kilanowski, A., Thiering, E., Wang, G., et al. Allergy. First published: 07 September 2022
Season of birth affects the risk of adult-onset asthma in Finland
Koskinen, A., Lemmetyinen, R., Luukkainen, A., et al. Allergy. First published: 06 September 2022
Mechanisms regulating neutrophil responses in immunity, allergy, and autoimmunity
Özcan, A. and Boyman, O. Allergy. First published: 06 September 2022
Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease
Xu, X., Reitsma, S., Wang, D.Y. and Fokkens, W.J. Allergy. First published: 06 September 2022
Resensitisation in suspected penicillin allergy
Doña, I., Guidolin, L., Bogas, G., et al. Allergy. First published: 06 September 2022
In vitro vaccine challenge of PBMCs from BNT162b2 anaphylaxis patients reveal HSP90α-NOD2-NLRP3 nexus
Ko, H.L., Zhuo, N., Chang, Z.W., et al. Allergy. First published: 03 September 2022
Sputum transcriptome analysis of co-regulated genes related to arachidonic acid metabolism in N-ERD
Mastalerz, L., Kacorzyk, R., Jakieła, B., et al. Allergy. First published: 01 September 2022
Citations: 1581
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Citations: 474
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
Citations: 272
COVID-19 in a designated infectious diseases hospital outside Hubei Province, China
Cai, Q., Huang, D., Ou, P., Yu, H., Zhu, Z., Xia, Z. et al. Allergy. 2020; 75: 1742– 1752
Citations: 255
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Citations: 242
Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors
Radzikowska, U., Ding, M., Tan, G., Zhakparov, D., Peng, Y., Wawrzyniak, P. et al. Allergy. 2020; 75: 2828– 2844
Citations: 192
TSLP and IL-33 reciprocally promote each other's lung protein expression and ILC2 receptor expression to enhance innate type-2 airway inflammation
Toki, S, Goleniewska, K, Zhang, J, et al. Allergy. 2020; 75: 1606– 1617
Citations: 175
Eleven faces of coronavirus disease 2019
Dong, X., Cao, Y.-Y., Lu, X.-X., Zhang, Du, H., J.-J., Yan, Y.-Q. et al. Allergy. 2020; 75: 1699– 1709
Citations: 117
Type 2 immunity in the skin and lungs
Akdis, CA, Arkwright, PD, Brüggen, MC, et al. Allergy. 2020; 75: 1582– 1605
Citations: 97
The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma
Eguiluz-Gracia, I, Mathioudakis, AG, Bartel, S, et al. Allergy. 2020; 75: 2170– 2184
Citations: 92
Towards a more precise diagnosis of hypersensitivity to beta-lactams — an EAACI position paper
Romano, A, Atanaskovic-Markovic, M, Barbaud, A, et al. Allergy. 2020; 75: 1300– 1315
Citations: 90
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma
Agache, I, Song, Y, Posso, M, et al. Allergy. 2021; 76: 45– 58
Citations: 89
Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2
Zhang, J.-j., Cao, Y.-y., Dong, X., Wang, B.-c., Liao, M.-y., Lin, J. et al. Allergy. 2020; 75: 1809-1812
Citations: 88
Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status
Du, H, Dong, X, Zhang, J-J, et al. Allergy. 2021; 76: 510– 532
Citations: 83
Is asthma protective against COVID-19?
Carli, G., Cecchi, L., Stebbing, J., Parronchi, P. and Farsi, A. Allergy.2021; 76: 866-868
Citations: 81
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement
Bousquet, J., Akdis, C.,A., Jutel, M., Bachert, C., Klimek, L., Agache, I. et al. Allergy. 2020; 75: 2440-2444
Citations: 81
Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?
Gursel, M. and Gursel, I. Allergy. 2020; 75: 1815-1819
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, et al. Allergy. 2022; 77: 734– 766
The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Advances and recent developments in asthma in 2020
Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541
Drug hypersensitivity, in vitro tools, biomarkers, and burden with COVID-19 vaccines
Palomares, F., Paris, J.L., Labella, M., Doña, I., Mayorga, C. and Torres, M.J. Allergy. First published: 01 August 2022
SARS-CoV-2 infection in severe asthma is associated with worsening of COVID-19 through respiratory NLRP3 inflammasome activation
Jeong, J.S., Choi, J.Y., Kim, J.S., et al. Allergy. First published: 24 July 2022
Exposure to avian coronavirus vaccines is associated with increased levels of SARS-CoV-2-cross-reactive antibodies
Ardicli, O, Carli, KT, Satitsuksanoa, P, et al. et al. Allergy. First published: 23 July 2022
Urticaria and/or angioedema secondary to mRNA COVID-19 vaccines: Updates from a United States case registry
Anvari, S., Samarakoon, U., Fu, X., et al. Allergy. First published: 16 July 2022
The nasopharyngeal and salivary microbiomes in COVID-19 patients with and without asthma
Kim, J.G., Zhang, A., Rauseo, A.M., et al. Allergy. First published: 15 July 2022
Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity
Worm, M., Alexiou, A., Bauer, A., et al. Allergy. First published: 20 June 2022
Presentation of airway and general symptoms in COVID-19 caused by dominant SARS-CoV-2 variants: a follow-up on ARIA consensus
et al. Allergy. First published: 14 June 2022
Immune-inflammatory proteome of elite ice hockey players before and after SARS-CoV-2 infection
Maurer, D.J., Barletta, E., Heider, A., et al. Allergy. First published: 12 June 2022
Combined assessment of S- and N-specific IL-2 and IL-13 secretion and CD69 neo-expression for discrimination of post–infection and post-vaccination cellular SARS-CoV-2-specific immune response
Kratzer, B., Schlax, L.C., Gattinger, P., et al. Allergy. First published: 12 June 2022
T cell recovery and evidence of persistent immune activation 12 months after severe COVID-19
Taeschler, P., Adamo, S., Deng, Y., et al. Allergy. First published: 14 May 2022
Long-term effects of homologous and heterologous SARS-CoV-2 vaccination on humoral and cellular immune responses
Hollstein, M.M., Münsterkötter, L., Schön, M.P., et al. Allergy. First published: 14 May 2022
COVID-19 in the absence of eosinophils: The outcome of confirmed SARS-CoV-2 infection whilst on treatment with benralizumab
Francis, C.H.R., Hearn, A.P., Ratnakumar, S., et al. Allergy. First published: 01 May 2022
Effect of BTN162b2 and Coronavac boosters on humoral and cellular immunity of individuals previously fully vaccinated with Coronavac against SARS-CoV-2: A longitudinal study
Kuloğlu, Z.E., El, R., Guney-Esken, et al. Allergy. First published: 19 April 2022
Intranasal administration of a VLP-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern
Rothen, D.A., Krenger, P.S., Nonic, A., et al. Allergy. First published: 11 April 2022
Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures
Taeschler, P., Cervia, C., Zurbuchen, Y., et al. Allergy. First published: 01 April 2022
Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants
Gattinger, P., Kratzer, B., Tulaeva, I., et al. Allergy. First published: 31 March 2022
Are health care policies for COVID-19 evidence-based?
Bonini, S. and Fiorito, S. Allergy. First published: 30 March 2022
Virus-related stimuli modulate SARS-CoV-2 entry factor expression in pediatric tonsillar epithelial cells in vitro
Hara, M., Morimoto, N., Watabe, T., et al. Allergy. First published: 29 March 2022
Do basophil activation tests help elucidate allergic reactions to the ingredients in COVID-19 vaccines?
Eberlein, B., Sonja, M., Fischer, J., Darsow, U., Biedermann, T. and Brockow, K. Allergy. First published: 10 March 2022
Humoral immune response of Sinopharm/BBIBP COVID-19 vaccination before and after the booster immunization
Cheng, Z.J., Huang, H., Zheng, P., et al. Allergy. First published: 07 March 2022
August 2022 - COVID vaccines and new variants: the light at the end of the tunnel
Volume 77 | Issue 8
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review
Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027
CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. 2021; 76: 3028-3040
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study
Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052
Direct assessment of individual skin barrier components by electrical impedance spectroscopy
Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106
Prenatal paraben exposure and atopic dermatitis-related outcomes among children
Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132
Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis
Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154
Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy
Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196
Transgenic mice overexpressing the PGE2 receptor EP2 on mast cells exhibit a protective phenotype in a model of allergic asthma
Urbano, A., Plaza, J., Turon, S., et al. Allergy. 2021; 76: 3196-3199
Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202
Identification of Ulocladium chartarum as an important indoor allergen source
Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206
Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis
Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Remington, B.C., Koppelman, S.J., Green, T.D., et al. Allergy. 2021; 76: 3223-3226
Legends of allergy and immunology: Sergio Bonini
Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229
Medical algorithm: Peri-operative management of mastocytosis patients
Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235
Junior Members Corner
Dear Junior Members,
The World Immune Regulation Meeting (WIRM) was held in Davos, Switzerland, from 6 to 9 July 2022 after two consecutive years with an online format
The meeting focused on “Immune Activation, Effector Functions and Immune Tolerance with a special focus on Autoimmunity and Allergy”. We had the opportunity to learn first-hand from more than 40 top-speakers from around the world. The topics, divided in twelve, ranged from T and B cell activation to immunity against viral infections -including COVID-19-, novel vaccine development and inflammation in cancer. In addition, we were able to enjoy 12 workshops with more than 60 speakers and 11 poster sessions with more than 70 presenters.
The congress was a total success! As in previous editions, the meeting allowed the participants to directly interact with top scientists in the field, not only during the meeting sessions and workshops, but also during the networking events and inspiring poster sessions while enjoying a delicious dinner. Not to mention the idyllic scenery of Davos and the warm welcome of the Swiss Institute of Allergy and Asthma Research (SIAF) members and the organising committee.
We encourage you to participate in the next WIRM, an ideal congress for both basic and clinical researchers, which will be held in 5-8 July 2023.
Keep you up to date with the latest news by clicking here
Best regards,
The Junior Member Assembly
